Steatohepatitis/Metabolic Liver Disease News

High-sensitivity cardiac troponin may be used as a marker for predicting coronary artery disease risk in patients with nonalcoholic fatty liver disease, according to a study published in Clinical Gastroenterology and Hepatology.

Lipocine announced positive results from its phase 2 proof of concept study that investigated LPCN 1144, an orally delivered prodrug of endogenous testosterone, in the treatment of nonalcoholic steatohepatitis, according to a press release.

The Nash-FibroTest non-invasive panel successfully diagnosed the stage of fibrosis as well as graded nonalcoholic steatohepatitis and steatosis among patients with type 2 diabetes, according to a recent study.

This month’s cover story puts forth a call to action for our fellow physicians to be more aware of fatty liver disease risk. But this call needs to be about more than awareness. It must be a call for multidisciplinary coordinated screening and follow-up.

Among patients with nonalcoholic fatty liver disease, AXA1125 showed greater activity over 16 weeks compared with AXA1957 and placebo, according to a study published in The American Journal of Gastroenterology.

Among a population with low consumption of red meat, those who consumed a high amount of red meat had a high chance for nonalcoholic fatty liver disease, according to a study published in the American Journal of Gastroenterology.

Healio Gastroenterology presents the following report on the top 10 peer-tested stories in July.

Patients with non-alcoholic fatty liver disease benefited from encouragement to complete a low-energy diet even if there were no adherence issues with intervention plans, according to results published in BMJ Open Gastroenterology.

Eight professional societies issued a joint report on the dangers associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, calling on clinicians to work together across specialties and align treatment strategies.

Combined serum circulating micro-RNA served as a novel biomarker for the diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease, according to research published in Nature Scientific Reports.